Clinical trials: Remission of Ulcerative Colitis
Ulcerative Colitis
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis
The aims of our study are to evaluate the feasibility and safety of endoscopic injection of adipose tissue-derived mesenchymal stem cells in human subjects with moderate active ulcerative colitis, assessing the absence of adverse…
- Trial name
- ALOASCU (NCT01914887)
- Testing
- Allogeneic adipose tissue-derived mesenchymal stem cells
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Colitis, Ulcerative
Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.
The purpose of this study is to test the long-term safety and tolerability of SPD476 in the maintenance of ulcerative colitis remission.
- Trial name
- NCT00151944
- Testing
- SPD476 (mesalazine)
- Volunteers
- 400 people
- Sponsor
- Shire
Ulcerative Colitis
Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.
The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as mesalazin in preventing an acute episode in ulcerative colitis.
- Trial name
- NCT00259571
- Testing
- retarded release phosphatidylcholine
- Where
- Germany
- Sponsor
- Heidelberg University
Ulcerative Colitis
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared…
- Trial name
- NCT01124149
- Testing
- MMX mesalamine/ mesalazine
- Where
- 105 sites in United States, Belgium and 13 more
- Volunteers
- 759 people
- Sponsor
- Shire
Ulcerative Colitis
Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment
For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for…
- Trial name
- IMPACT (NCT02261636)
- Testing
- mesalazine
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Ferring Pharmaceuticals
Disease Activity, Remission of Ulcerative Colitis
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis
Specialized pro-resolving mediators (SPMs), which are typically thought to be formed via consecutive steps of oxidation of polyenoic fatty acids, have been shown to suppress inflammation and promote timely resolution of…
- Conditions
- Disease Activity, Remission of Ulcerative Colitis, Ulcerative Colitis Flare
- Trial name
- NCT06652464
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center
Inflammatory Bowel Diseases, Remission
Assessing the Effectiveness of a Stress Reduction Intervention in Inflammatory Bowel Disease (IBD)
The investigators have designed a guided, online, tri-component, stress reduction intervention for participants with inflammatory bowel diseases.
- Conditions
- Inflammatory Bowel Diseases, Remission, Perceived Stress
- Trial name
- NCT03831750
- Testing
- Stress Reduction Intervention
- Where
- Canada
- Volunteers
- 101 people
- Sponsor
- University of Alberta
Ulcerative Colitis
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response…
- Trial name
- NCT02426372
- Testing
- QBECO SSI
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- Qu Biologics Inc.
Ulcerative Colitis
Golimumab Trough Levels in Patients With Ulcerative Colitis
Proactive therapeutic drug monitoring of Anti-TNFs with drug titration to a therapeutic window is associated with favorable long-term therapeutic outcomes in IBD and may be superior to reactive therapeutic drug monitoring.
- Trial name
- GLMLEVEL (NCT03773445)
- Testing
- Golimumab trough levels, Antibodies to golimumab, Histology
- Where
- 12 sites in Spain
- Volunteers
- 52 people
- Sponsor
- Hospital San Carlos, Madrid
Ulcerative Colitis
Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis
The purpose of this study is to compare the maintenance of mild to moderate ulcerative colitis remission with six months of treatment with 1.5 grams of mesalamine pellets each day versus placebo.
- Trial name
- NCT00767728
- Testing
- Granulated mesalamine
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and…
- Trial name
- SELECTION (NCT02914522)
- Testing
- Filgotinib, PTM filgotinib
- Where
- 343 sites in United States, Argentina and 38 more
- Volunteers
- 1,351 people
- Sponsor
- Gilead Sciences
Exclusive Enteral Nutrition, Ulcerative Colitis
Combined Application of EEN in the Induction of Remission in PUC
The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease had been well documented. But the role of EEN in children with Ulcerative Colitis (UC) was not clear.
- Conditions
- Exclusive Enteral Nutrition, Ulcerative Colitis, Children
- Trial name
- NCT04999241
- Testing
- exclusive enteral nutrition, regular food
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University
Ulcerative Colitis
Anal Manometry Examination in Patients With Ulcerative Colitis
Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic immune-related diseases.
- Trial name
- NCT05488041
- Testing
- Performing anorectal manometry
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- Assaf-Harofeh Medical Center
Ulcerative Colitis
Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis
Inflammatory Bowel Disease, including ulcerative colitis, is thought to result from an imbalance of pro-inflammatory and anti-inflammatory factors.
- Trial name
- NCT02683759
- Testing
- Bio-enhanced Curcumin Soft Gelatin Capsule, 5-Aminosalicyclic acid
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Asian Institute of Gastroenterology, India
Ulcerative Colitis, Flare Up, Symptom
Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab
TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerative colitis in Switzerland.
- Trial name
- NCT03394586
- Testing
- Exposure to golimumab
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Ulcerative Colitis
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
This is a multi-center, randomized, parallel arm, double-blind study with approximately 750 participants with moderately to severely active Colitis Ulcerosa randomized to receive either PB016 or Entyvio®
- Trial name
- UCESIVE (NCT05771155)
- Testing
- Intravenous (IV) infusions
- Where
- Georgia
- Volunteers
- 750 people
- Sponsor
- Polpharma Biologics S.A.
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis
Investigators aimed at investigating the prediction ability of faecal calprotectin to predict mucosal healing and histological remission in ulcerative colitis patients receiving biological therapy Investigators aimed to evaluate…
- Trial name
- NCT04818788
- Testing
- Biological Drug
- Volunteers
- 24 people
- Sponsor
- Assiut University
Ulcerative Colitis
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26…
- Trial name
- CAMPIII (NCT01004185)
- Testing
- Asacol 400 mg
- Where
- 51 sites in United States, Canada and 4 more
- Volunteers
- 39 people
- Sponsor
- Warner Chilcott